- Home
- IBOC vs APGE Comparison
IBOC vs APGE Comparison
Compare IBOC & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBOC | APGE |
|---|---|---|
| Founded | 1966 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.7B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | IBOC | APGE |
|---|---|---|
| Price | $66.69 | $74.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $85.00 | ★ $99.44 |
| AVG Volume (30 Days) | 314.2K | ★ 970.7K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 5.13 | N/A |
| EPS | ★ 6.76 | N/A |
| Revenue | ★ $821,716,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.83 | ★ N/A |
| Revenue Growth | ★ 2.80 | N/A |
| 52 Week Low | $54.11 | $26.20 |
| 52 Week High | $73.66 | $80.99 |
Technical Indicators
Market Signals| Indicator | IBOC | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 54.28 |
| Support Level | $67.61 | $74.89 |
| Resistance Level | $69.62 | $78.34 |
| Average True Range (ATR) | 1.46 | 2.82 |
| MACD | -0.63 | -0.94 |
| Stochastic Oscillator | 13.17 | 14.91 |
Price Performance
Historical ComparisonAbout IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.